Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI-Powered dermatoscope aims to spot skin cancer faster

NCT ID NCT03818620

Diagnosis Sponsor: Barco NV Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Oct 05, 2026 · Last updated Oct 06, 2026 · Updated 1 time

Summary

Researchers are testing a new digital dermatoscope called DermScan that uses automatic decision support to help identify skin cancer. The study enrolls adults with skin lesions and collects images with both the new device and a standard dermatoscope. The goal is to build a large database of anonymized images and compare how well the new device performs against standard care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Barco digital dermatoscope device
What this could lead to
If the device works well, it could help doctors detect skin cancer earlier and make dermatology exams more efficient.
What could go wrong
The device may not perform better than standard dermoscopy, and the AI algorithms need large, diverse datasets to work reliably. This observational study does not test whether the device improves patient outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

4,339 people

The number who actually took part.

Started

Jun 2017

Finished

May 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients will be considered for enrollment in the study when they have a lesion that is accessible to the Barco Digital Dermatoscope, are able to give informed consent and are over 18 years old.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * The patient has a lesion that is accessible to the Barco Digital Dermatoscope * Patient gives informed consent * Men or women of any ethnic group aged ≥ 18 years Exclusion Criteria: * Men or women of any ethnic group aged \< 18 years * Patients not willing or able to read, understand and sign the study-specific informed consent form

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Skin cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

skin cancer skin disorder skin neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Skin cancer Skin diseases

Contacts and locations

Locations

  • UZ / KU Leuven

    Leuven, 3000, Belgium

  • UZ Gent

    Ghent, 9000, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.